Intech Investment Management LLC Acquires 16,212 Shares of AstraZeneca Plc $AZN

Intech Investment Management LLC increased its holdings in shares of AstraZeneca Plc (NYSE:AZN – Free Report) by 13.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 134,037 shares of the company’s stock after acquiring an additional 16,212 shares during the quarter. Intech Investment Management LLC’s holdings in AstraZeneca were worth $21,866,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Amundi lifted its holdings in shares of AstraZeneca by 6.7% in the 2nd quarter. Amundi now owns 16,422,784 shares of the company’s stock worth $3,114,088,000 after purchasing an additional 1,036,635 shares during the last quarter. Janus Henderson Group PLC grew its holdings in AstraZeneca by 889.9% in the 1st quarter. Janus Henderson Group PLC now owns 11,949,424 shares of the company’s stock worth $2,319,947,000 after buying an additional 10,742,268 shares in the last quarter. Royal Bank of Canada grew its stake in shares of AstraZeneca by 208.6% in the first quarter. Royal Bank of Canada now owns 10,386,455 shares of the company’s stock worth $2,048,417,000 after purchasing an additional 7,021,126 shares in the last quarter. Fisher Asset Management LLC grew its position in AstraZeneca by 3.2% in the 3rd quarter. Fisher Asset Management LLC now owns 11,501,748 shares of the company’s stock valued at $1,857,187,000 after buying an additional 355,456 shares in the last quarter. Finally, Rathbones Group PLC boosted its holdings in shares of AstraZeneca by 106,772.0% in the first quarter. Rathbones Group PLC now owns 8,054,943 shares of the company’s stock valued at $1,560,419,000 after acquiring an additional 8,047,406 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

AZN has been the topic of a number of research analyst reports. Deutsche Bank raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, September 15th. Weiss Ratings upgraded shares of AstraZeneca from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, October 26th. Royal Bank Of Canada initiated coverage on AstraZeneca in a report on Tuesday, September 8th. They issued an “outperform” rating on the stock. CICC Research began coverage on shares of AstraZeneca in a research report on Sunday, August 23rd. They issued an “outperform” rating and a $198.00 price target for the company. Finally, Zacks Research upgraded shares of AstraZeneca from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 13th. Sixteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $206.67.

Get Our Latest Report on AstraZeneca

AstraZeneca Stock Performance

Shares of NYSE AZN opened at $184.66 on Monday. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.01 and a quick ratio of 0.79. AstraZeneca Plc has a one year low of $153.41 and a one year high of $212.71. The business’s 50-day moving average price is $168.82 and its two-hundred day moving average price is $180.20. The company has a market capitalization of $286.40 billion, a P/E ratio of 26.12, a price-to-earnings-growth ratio of 1.43 and a beta of 0.24.

AstraZeneca (NYSE:AZN – Get Free Report) last posted its quarterly earnings results on Friday, October 30th. The company reported $2.79 earnings per share for the quarter, topping analysts’ consensus estimates of $2.60 by $0.19. AstraZeneca had a return on equity of 31.85% and a net margin of 17.68%. The company had revenue of $16.21 billion during the quarter, compared to the consensus estimate of $16 billion. During the same period last year, the business earned $2.38 EPS. The business’s quarterly revenue was up 6.5% on a year-over-year basis. Analysts anticipate that AstraZeneca Plc will post 10.22 earnings per share for the current fiscal year.

About AstraZeneca

(Free Report)

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.

Further Reading

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca Plc (NYSE:AZN – Free Report).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.